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Abstract
Background: Circulating cell-free microRNAs have been identified as potential cancer biomarkers. However, the
existence and the potential application of cell-free miRNAs in effusion samples are still uncertain. In order to
explore the potential role of cell-free miRNA in malignant effusions, we selected 22 miRNAs differentially expressed
in the serum of lung cancer patients and studied their expression levels in body cavity effusion samples.
Methods: We measured the expression of 22 miRNAs using qRT-PCR in two samples, which were pooled with 18
malignant and 12 benign effusions, respectively. After discarding 9 lowly expressed miRNAs, a panel of 13 miRNAs
were measured in 29 samples (benign n = 11, malignant n = 18). We also carried out a WST-8 test to evaluate the
docetaxel sensitivity of tumor cells directly isolated from 15 malignant effusions.
Results: We compared the miRNA expression levels between benign and malignant effusions using a Mann-
Whitney U test and found miR-24, miR-26a and miR-30d were expressed differently between the two groups (P =
0.006, 0.021 and 0.011, respectively). Cells isolated from effusions rich in cell-free miR-152 were more sensitive to
docetaxel (r = 0.60, P = 0.016).
Conclusions: Collectively, our study demonstrated that cell-free miRNAs in the supernatant of effusions may aid in
the diagnosis of malignancy and predict chemosensitivity to docetaxel.
Background
Body cavity effusion is a clinical common manifestation
and may cause dilemmas in treatment. Diagnosis of effu-
sions is of particular importance for cancer patients and a
co-existing malignant effusion implies an advanced stage
of tumor and intricate clinical management. Currently,
diagnosis of malignant effusions mainly relies on cytologi-
cal analysis. However, the sensitivity is still limited to
about 70% even with repeated analyses [1]. Thus, alterna-
tive diagnostic methods are still in need to assist in the
diagnosis of effusions. The supernatant of effusion samples
may contain useful information in the form of proteins
and nucleic acids. Tumor marker proteins [2], DNA
methylation status [3] and cell-free mRNA levels [4] have
been identified as potential biomarkers with limited
improvement in diagnostic accuracy.
MicroRNAs (miRNAs) are a group of short RNAs that
post-transcriptionally regulate expression of proteins by
binding to the 3’UTRs of target mRNAs. miRNAs are
involved in the development of cancer and specific
miRNA expression profile may suggest not only the dis-
ease status but also the prognosis and response to che-
motherapeutic reagents [5,6]. Accumulating evidence
suggested circulating cell-free miRNAs as potential bio-
markers for disease status, such as liver injury [7], diabetes
[8], myocardial infarction [9] and more importantly, can-
cer [8,10]. Specific circulating miRNA profiles may act as
novel biomarkers for cancer diagnosis and early detection.
Thus, we hypothesized that malignant effusions may have
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information regarding the presence of tumor cells. We
chose a panel of miRNAs that were deregulated in the
serum of lung cancer patients and explored their possible
role in malignant effusions. We also correlated the level of
cell-free miRNA with sensitivity of tumor cells against
docetaxel, a microtubule stabilizer widely used in cancer
management.
Methods
Samples collection and Patients Information
Our study was approved by the Ethics Review Board of
Nanjing University, Nanjing, China. Informed consent
was obtained from all patients. All effusion samples
were recruited from the Affiliated Drum Tower Hospi-
tal, Medical School of Nanjing University, from Jan 2006
to Dec 2007. Malignant effusions were confirmed by
pathological diagnosis. Samples were collected before
chemotherapy. Effusions were diagnosed as benign
based on the clinical context and the absence of malig-
nant cells in 3 separate samples from the same patients.
No cancers occurred in patients with benign effusions
over the next 6 months. All samples were transported to
the laboratory within 30 min after their collection. The
information for patients is presented in Table 1.
Chemotherapeutic agent and chemosensitivity test
Primary tumor cells were prepared by Ficoll-Hypaque
(specific gravity 1.077, Pharmacia) density centrifugation.
The number and viability of cells were determined by
cytological examination with trypan blue dye. The test
drug concentration of docetaxel (DOC, donated by
Jiangsu Hengrui Medicine Company, purity > 99.9%)
was 12.4 μM, derived from pharmacokinetic data and
adjusted for protein-binding to approximate the concen-
tration achievable in the patient plasma. Cells were
seeded in U-shape-96-well plates at 5× 10
4 cells/well
and treated with drugs in triplicate for 72 h. WST-8
reagent (10 μl each) from Cell Counting Kit-8 (Dojindo,
Kumamoto, Japan) was added and absorbance was
determined with a multiwell spectrophotometer (BioTek,
VT, USA) at 460 nm. Inhibition rate = (1-absorbance of
treated cells/control cells) ×100%. Only the specimens
containing at least 50% cancer cells were enrolled for
chemosensitivity test. And we have proved the increase
of tumor cells number by the culture in our preliminary
test. Serum free medium and polypropylene U-shape-
96-well microplates can enrich tumor cells up to 80-
90% [11].
Quantitative RT-PCR (qRT-PCR) analysis of miRNA
expression
Samples for miRNA quantification were centrifuged at
8000 g for 20 min and the supernatants were collected.
After adding 750 μlT r i z o lL S( I n v i t r o g e n ,C A ,U S A )
into 250 μl effusion samples, another 25 μl ath-miR156a
(20 nM, synthesized by Takara, Japan) was supplemen-
ted into each sample tube. Total RNA was extracted
using Trizol LS reagent (Invitrogen, CA, USA) according
to the manufacture’s instruction. The miRNA expression
levels were quantified by real-time PCR using miRNA
detection kit (Applied Biosystems, Foster city, CA,
USA). Briefly, miRNAs were reverse-transcribed to
cDNA with the AMV reverse transcriptase (Takara,
Japan). Subsequently, real-time PCR was performed on
Mx3000P cycler (Stratagene, USA). All reactions were
run in triplicate. Ct data were determined using default
threshold settings. The relative expression levels of miR-
NAs were calculated as 2
-ΔΔCt [12], using ath-miR156a
as reference and a mixture of RNA extracted from
human lung cancer A549 cells and gastric cancer BGC-
823 cells (1:1) as the calibrator.
Statistics
Mann-Whitney U test was used to compare the expres-
sion of each miRNA between malignant and benign
groups. Spearman correlation coefficient was used to
analyze the relationship between miRNA levels and inhi-
bition rates of docetaxel on tumor cells. All these statis-
tics were done by a statistics program, SPSS version
13.1 (SPSS Inc, Chicago, IL, USA). A P value < 0.05
(two tailed) was considered statistically significant.
Table 1 Patient characteristics
Characteristics Number Percent (%)
Malignant 18
Gastric cancer 9 50
Lung cancer 9 50
Gender Male 9 50
Female 9 50
Age < 60 7 39
>6 0 1 1 6 1
Benign 11
Ascites 4 36
Pleural 7 64
Gender Male 6 55
Female 5 45
Age < 60 6 56
>6 0 5 4 5
Diagnosis
Liver Cirrhosis 2 18
Tuberculosis 3 27
Heart Failure 3 27
Pneumonia 2 18
Injury 1 9
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The stability of miRNAs in the effusion samples
We firstly tested the stability of cell-free miRNAs in
the effusion samples kept at room temperature for dif-
ferent time periods, or treated with multiple freezing
and thawing, and digestion with RNase or DNase. b-
actin mRNA transcripts and 18S RNA representing
large molecular RNAs were analyzed in this study.
qRT-PCR was carried out to quantify the RNAs of
three samples with various treatments. Multiple freeze-
thaw cycles had hardly any effect on cell-free RNAs in
effusion samples (Figure 1A). When effusion samples
were left at room temperature for 3 h or 24 h, cell-free
RNAs began to degrade at 3 h. b-actin mRNA
degraded quickly and significantly, while 18S RNA and
the two miRNAs were more stable, with more than
20% remaining after 24 h (Figure 1B). When treated
with RNase, miRNAs were more stable than large
RNA molecules although significant deposition also
occurred in miRNAs. All cell-free RNAs were resistant
to DNase digestion (Figure 1C).
Expression levels of cell-free miRNAs in malignant and
benign effusion samples
In order to evaluate the miRNAs expression in the
supernatant of effusion samples, we selected 22 miRNAs
from the list of deregulated cell-free miRNAs in the
serum of lung cancer patients published previously [8].
qRT-PCR was used to examine the possible expression
levels in two samples, which were pooled from 18
malignant and 12 benign effusions (equivalent amounts
of RNA were added to each sample). Ct values of each
miRNAs were obtained and assessed. miRNAs with Ct
>35 were discarded, resulting in 13 miRNAs (Table 2).
Next, we measured the expression levels of 13 miR-
NAs in 29 samples (benign n = 11; malignant n = 18).
The expression levels of the 13 miRNAs were compared
between malignant and benign groups using a Mann-
Whitney U test. miR-24, miR-26a and miR-30d were
expressed significantly differently between groups (P =
0.006, 0.021 and 0.011, respectively). All three miRNAs
were significantly over-expressed in the supernatant of
malignant effusions (Figure 2). However, no significant
Figure 1 Stability of cell-free RNAs in body cavity effusion samples. Effusion samples (n = 3) was subjected to 10 freeze-thaw cycles (A),
room temperature conservation for 3 h or 24 h (B) and RNase or DNase digestion for 3 h at 37°C (C). Total RNA was extracted from the effusion
samples. The levels of miRNA or other RNAs were determined using qRT-PCR with 40 cycles. Column, relative expression levels of RNA compared
to samples without treatment; bars, SD; ACTB: b-actin.
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the three miRNAs differently expressed between malig-
nant and benign groups.
Cell-free miRNAs in effusion samples may predict cell
sensitivity against docetaxel
T h eW S T - 8t e s th a sb e e nc o n f i r m e dt ob ear e l i a b l e
chemosensitivity test for primary tumor cells of malig-
nant effusions [13]. In the current study, the chemosen-
sitivity of primary tumor cells isolated from fifteen
malignant effusion samples were examined. The mean
inhibition rate was 0.49 (range: 0.2 to 0.86, n = 15).
Malignant effusion samples with an inhibition rate <
mean were considered docetaxel resistant, and those
with an inhibition rate ≥ mean were considered as doce-
taxel sensitive. The docetaxel sensitive group has a
higher level of cell-free miR-152 in the effusion superna-
tant (P = 0.005, Figure 3A). Spearman correlation coeffi-
cient was also used to compare the miRNAs expression
levels and sensitivity. The expression levels of miR-152
correlated with the inhibition rates of docetaxel (r =
0.60, P = 0.016, Figure 3B). miR-320 expression levels
were also associated with docetaxel inhibition rates (r =
0.52, P = 0.042), but no significant difference on miR-
320 expression levels was observed between docetaxel
resistant and sensitive groups (P = 0.087).
Discussion
In the current study, we explored the expression of cell-
free miRNAs in malignant effusion samples, and found
that malignant effusions have higher expression levels of
miR-24, miR-26a and miR-30d. This suggests that
malignant effusions may have a different cell-free
miRNA expression profile. miR-24, miR-26a and miR-
30d are differentially expressed in a panel of cancers
[14-17]. Chen et al [8] demonstrated that these three
miRNAs were highly expressed in the serum of lung
cancer patients compared to healthy control. Our result
is in accordance with the result in the serum of lung
cancer patients.
This study also revealed that effusion samples with
tumor cells resistant to docetaxel contain lower levels of
Table 2 Initial evaluation of expression levels for
22 miRNAs
miRNA Ct value
Sample B Sample M
miR-20a 29.85 27.74
miR-21 30 26.62
miR-22 35.63 33.1
miR-24 33.06 29.35
miR-25 33.17 31.75
miR-26a 30.96 27.91
miR-26b 33.26 31.69
miR-27a 35.96 33.24
miR-27b 35.47 33.74
miR-29a 34.11 34.58
miR-30d 34.52 30.15
miR-145 35.91 36.51
miR-146a 28.61 28.8
miR-152 33.95 31.75
miR-199a No Ct 37.9
miR-200c 35.31 34.15
miR-221 36.05 34.25
miR-222 29.87 27.46
miR-223 29.3 27.45
miR-320 25 23.28
miR-375 No Ct No Ct
miR-382 No Ct No Ct
Sample B: the benign sample pooled from 5 ascites and 7 pleural effusions
Sample M: the malignant sample pooled from 9 ascites and 9 pleural
effusions
Figure 2 Expression levels of miR-24, miR-26a and miR-30d in effusion samples. (A) The expression levels of miR-24 were higher in
malignant effusions (n = 18) than benign effusions (n = 11 P = 0.006); (B) The expression levels of miR-26a were higher in malignant effusions
(n = 18) than benign effusions (n = 11, P = 0.021); (C) The expression levels of miR-30d were higher in malignant effusions (n = 18) than benign
effusions (n = 11, P = 0.011).
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tumor cells. We demonstrated for the first time that
cell-free miRNAs may be potential diagnostic biomar-
kers for diagnosis and drug sensitivity.
Currently used biomarkers mainly rely on tumor spe-
cific peptides derived from proteomic profiling [18].
However, as tumor-associated proteins constitute only a
minor fraction compared with normal proteins, the sen-
sitivity for these “tumor proteins” may be limited. Cell-
free nucleic acids have recently attracted interest as the
diagnostic biomarkers for cancer. Several studies have
focused on cell-free nucleic acids from fluid samples
and explored their potential application as diagnostic
biomarkers [4], [19]. Up to now, cell-free miRNAs have
been studied well in plasma, serum, urine [20], saliva
[21] and sputum [22]. Recently published reports proved
that cell-free miRNAs in plasma or serum are stable and
can be used to distinguish cancer patients from healthy
subjects [8,10,23]. In view of the success of cell-free
miRNAs of other body fluids in cancer diagnosis and
the results of this study, cell-free miRNAs may serve as
novel diagnostic biomarkers in the diagnosis of body
cavity effusions with minimal invasiveness and sample
requirement.
Docetaxel is a tubulin-binding agent that induces cell
death through stabilizing microtubules after binding to
b-tubulin. Interogation of miRGen, a web tool for
miRNA target prediction and function [24], revealed a
group of microtubule related genes that may be poten-
tial targets of miR-152, including b- tubulin2b, b-tubulin
4q-chain, b-tubulin 6 and b-tubulin 8. A group of ATP-
binding cassettes (ABC) transporters was also identified
as potential targets of miR-152, including ABCA1,
ABCB7 and ABCD3. Chemotherapeutic resistance of
tumor cells may be due to the drug pumps, which are
mainly made up of ABC proteins [25]. These two types
of possible targets may explain partly the reason for
lower expression of cell-free miR-152 in docetaxel resis-
tant group. However, data is still scarce and further
research is needed.
Conclusions
In summary, we showed that malignant effusion superna-
tant had a different profile of miRNAs when compared to
benign samples. The expression levels of cell-free miR-
152 may discriminate docetaxel sensitive samples from
resistant samples. Given the results from this study, addi-
tional potential markers may be revealed by more sys-
tematic miRNA profiling in the future.
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